78 Les biomarqueurs moléculaires en oncologie
8. Tefferi, A. (2013) Polycythemia vera and essential thrombocythemia: 2013 update on
diagnosis, risk-stratification, and management. Am. J. Hematol. 88: 507–516
9. Tefferi A. (2013) Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and
management. Am J Hematol.88:141-50 (Erratum in: Am J Hematol. 88: 437-45)
10. Klampfl T, Gisslinger H, Harutyunyan AS, et al (2013) Somatic mutations of calreticulin
in myeloproliferative neoplasms. N Engl J Med 369: 2379-2390
11. Kouroupi E, Kiladjian JJ, Dosquet C, et al. (2012) Does increasing the JAK2V617F assay
sensitivity allow to identify more patients with MPN? Blood Cancer J. 2 :e70.
12. Jovanovic JV, Ivey A, Vannucchi AM, et al. (2013) Establishing optimal quantitativepolymerase chain reaction assays for routine diagnosis and tracking of minimal residual
disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European
LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia 27:
2032-9
13. Hussein K, Bock O, Theophile K, et al. (2009) JAK2(V617F) allele burden discriminates
essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp
Hematol 37: 1186-1193
14. Tefferi A, Thiele J, Vannucchi AM, et al. (2014) An overview on CALR and CSF3R
mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative
neoplasms. Leukemia. [epub ahead of print]
15. Barbui T, Finazzi G and Anna Falanga (2013). Myeloproliferative neoplasms and
thrombosis. Blood 122: 2176-2184
16. Rumi E, Pietra D, Ferretti V, et al. (2014) JAK2 or CALR mutation status defines subtypes
of essential thrombocythemia with substantially different clinical course and outcomes.
Blood. 123: 1544-51
17. Guglielmelli P, Barosi G, Specchia G, et al. (2009) Identification of patients with poorer
survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.
Blood.114: 1477-8
18. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA (2011) New mutations
and pathogenesis of myeloproliferative neoplasms. Blood. 118: 1723-35
19. Vannucchi AM, Lasho TL, Guglielmelli P, et al. (2013) Mutations and prognosis in primary
myelofibrosis. Leukemia 27: 1861-1869.
20. Tefferi A, Lasho TL, Finke CM, et al. (2014) CALR vs JAK2 vs MPL-mutated or triplenegative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. [epub
ahead of print].
21. Herishanu Y, Katz BZ, Lipsky A and Wiestner A (2013) Biology of Chronic Lymphocytic
Leukemia in Different Microenvironments: Clinical and Therapeutic Implications Hematol
Oncol Clin North 27: 173–206
22. Hallek M, Cheson BD, Catovsky D, et al. (2008) Guidelines for the diagnosis and
treatment of chronic lymphocytic leukemia: a report from the International Workshop on
Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group
1996 guidelines. Blood 111: 5446-5456
23. Langerak AW, Davi F, Ghia P, et al. (2011) European Research Initiative on CLL (ERIC).
Immunoglobulin sequence analysis and prognostication in CLL: guidelines from the ERIC
review board for reliable interpretation of problematic cases. Leukemia 25: 979-84
24. Hamblin TJ, Davis Z, Gardiner A, et al. (1999) Unmutated Ig V(H) genes are associated
with a more aggressive form of chronic lymphocytic leukemia. Blood 94: 1848-54
25. Pospisilova S, Gonzalez D, Malcikova Jv (2012) European Research Initiative on CLL
(ERIC). ERIC recommendations on TP53 mutation analysis in chronic lymphocytic
leukemia. Leukemia 26: 1458-61
26. Zenz T, Eichhorst B, Busch R, et al. (2010) TP53 mutation and survival in chronic
lymphocytic leukemia. J Clin Oncol. 28: 4473-9
27. Letestu R, Lévy V, Eclache V, et al. (2010) Prognosis of Binet stage A chronic lymphocytic
leukemia patients: the strength of routine parameters.Blood. 116: 4588-90
8. Tefferi, A. (2013) Polycythemia vera and essential thrombocythemia: 2013 update on
diagnosis, risk-stratification, and management. Am. J. Hematol. 88: 507–516
9. Tefferi A. (2013) Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and
management. Am J Hematol.88:141-50 (Erratum in: Am J Hematol. 88: 437-45)
10. Klampfl T, Gisslinger H, Harutyunyan AS, et al (2013) Somatic mutations of calreticulin
in myeloproliferative neoplasms. N Engl J Med 369: 2379-2390
11. Kouroupi E, Kiladjian JJ, Dosquet C, et al. (2012) Does increasing the JAK2V617F assay
sensitivity allow to identify more patients with MPN? Blood Cancer J. 2 :e70.
12. Jovanovic JV, Ivey A, Vannucchi AM, et al. (2013) Establishing optimal quantitativepolymerase chain reaction assays for routine diagnosis and tracking of minimal residual
disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European
LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia 27:
2032-9
13. Hussein K, Bock O, Theophile K, et al. (2009) JAK2(V617F) allele burden discriminates
essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp
Hematol 37: 1186-1193
14. Tefferi A, Thiele J, Vannucchi AM, et al. (2014) An overview on CALR and CSF3R
mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative
neoplasms. Leukemia. [epub ahead of print]
15. Barbui T, Finazzi G and Anna Falanga (2013). Myeloproliferative neoplasms and
thrombosis. Blood 122: 2176-2184
16. Rumi E, Pietra D, Ferretti V, et al. (2014) JAK2 or CALR mutation status defines subtypes
of essential thrombocythemia with substantially different clinical course and outcomes.
Blood. 123: 1544-51
17. Guglielmelli P, Barosi G, Specchia G, et al. (2009) Identification of patients with poorer
survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.
Blood.114: 1477-8
18. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA (2011) New mutations
and pathogenesis of myeloproliferative neoplasms. Blood. 118: 1723-35
19. Vannucchi AM, Lasho TL, Guglielmelli P, et al. (2013) Mutations and prognosis in primary
myelofibrosis. Leukemia 27: 1861-1869.
20. Tefferi A, Lasho TL, Finke CM, et al. (2014) CALR vs JAK2 vs MPL-mutated or triplenegative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. [epub
ahead of print].
21. Herishanu Y, Katz BZ, Lipsky A and Wiestner A (2013) Biology of Chronic Lymphocytic
Leukemia in Different Microenvironments: Clinical and Therapeutic Implications Hematol
Oncol Clin North 27: 173–206
22. Hallek M, Cheson BD, Catovsky D, et al. (2008) Guidelines for the diagnosis and
treatment of chronic lymphocytic leukemia: a report from the International Workshop on
Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group
1996 guidelines. Blood 111: 5446-5456
23. Langerak AW, Davi F, Ghia P, et al. (2011) European Research Initiative on CLL (ERIC).
Immunoglobulin sequence analysis and prognostication in CLL: guidelines from the ERIC
review board for reliable interpretation of problematic cases. Leukemia 25: 979-84
24. Hamblin TJ, Davis Z, Gardiner A, et al. (1999) Unmutated Ig V(H) genes are associated
with a more aggressive form of chronic lymphocytic leukemia. Blood 94: 1848-54
25. Pospisilova S, Gonzalez D, Malcikova Jv (2012) European Research Initiative on CLL
(ERIC). ERIC recommendations on TP53 mutation analysis in chronic lymphocytic
leukemia. Leukemia 26: 1458-61
26. Zenz T, Eichhorst B, Busch R, et al. (2010) TP53 mutation and survival in chronic
lymphocytic leukemia. J Clin Oncol. 28: 4473-9
27. Letestu R, Lévy V, Eclache V, et al. (2010) Prognosis of Binet stage A chronic lymphocytic
leukemia patients: the strength of routine parameters.Blood. 116: 4588-90